JBCHEPHARM
HealthcareJB Chemicals & Pharmaceuticals Limited
₹2,416.10
-89.90(-3.59%)
EMA 9: 2431.06EMA 21: 2362.93RSI: 62.1MACD: 71.81ATR: 58.99
Overlays
RSI (14)
Open
₹2,506.00
High
₹2,525.50
Low
₹2,380.00
Close
₹2,416.10
Volume
47,74,191
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) last closed at ₹2,416.1 on 16 Jul 2026, 4.3% below its 52-week high. Price is above both the 50-day and 200-day averages. Volume in the last session was 7.5 times the 20-day average. The scanner has no active condition on this stock right now.
1 week
-1.2%
1 month
+10.2%
3 months
—
52-week high
₹2,525.5
-4.3% from high
52-week low
₹1,720.6
Volume vs 20-day
7.49×
Active signals
No scanner condition is active on JBCHEPHARM today.
Signal history
| Dates | Signal | Type | Lasted | Quality | Move |
|---|---|---|---|---|---|
| 16 Jul | 20-Day High Breakout | BULLISH | 1d | Q77 | — |
| 14 Jul – 16 Jul | Volume Breakout | BULLISH | 3d | Q89 | -2.9% |
| 13 Jul – 15 Jul | RSI Overbought Zone | NEUTRAL | 3d | Q17 | +1.9% |
| 10 Jul | Strong Uptrend Alignment | BULLISH | 1d | Q79 | — |
| 07 Jul – 08 Jul | Volume Breakout | BULLISH | 2d | Q94 | +0.6% |
| 03 Jul – 07 Jul | 20-Day High Breakout | BULLISH | 3d | Q80 | +2.4% |
| 03 Jul – 09 Jul | RSI Overbought Zone | NEUTRAL | 5d | Q20 | +3.4% |
| 29 Jun – 01 Jul | 20-Day High Breakout | BULLISH | 3d | Q89 | -0.2% |
| 29 Jun – 30 Jun | Volume Breakout | BULLISH | 2d | Q89 | -0.3% |
| 23 Jun – 02 Jul | Strong Uptrend Alignment | BULLISH | 7d | Q66 | +3.8% |
Healthcare peers
| Stock | Price | Day | 1 month | RSI |
|---|---|---|---|---|
| PPLPHARMA | ₹242.75 | -0.73% | +24.9% | 68.1 |
| DIVISLAB | ₹11,060 | -3.34% | +22.5% | 67.4 |
| MAXHEALTH | ₹1,008 | +6.43% | +17.5% | 73.4 |
| GLENMARK | ₹2,625 | -0.57% | +16.6% | 67.8 |
| DRREDDY | ₹1,372.3 | -0.56% | +12.6% | 67 |
| MANKIND | ₹2,617.8 | -0.84% | +11.5% | 62.5 |
| APOLLOHOSP | ₹8,750 | +2.63% | +10.9% | 63.9 |
| GLAND | ₹3,390 | +1.68% | +10.6% | 71.2 |
| JBCHEPHARM | ₹2,416.1 | -3.59% | +10.2% | 62.2 |
Technical data for educational purposes only — not investment advice